Real-world safety study of desidustat for kidney anemia
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tracks the real-world safety of desidustat in adults with anemia caused by chronic kidney disease (CKD). It’s meant to see whether the medicine is safe when used in everyday care, not just in tightly controlled settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a current diagnosis of CKD-related anemia.
- Your hemoglobin level is between 7.0 and 11.0 g/dL (inclusive) before joining.
- You can understand the study and sign informed consent.
- You do not have a significant lack of folate or vitamin B12.
- If you’re on hemodialysis: you get dialysis at least 2 times per week for 12+ weeks and have a working access line (fistula, graft, or catheter).
- You haven’t had a red blood cell transfusion in the last 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This study is testing a new way to manage anemia (low red blood cells) in people on long-term dialysis. It aims to improve how doctors treat this common issue.
This study tests a daily pill that helps people with chronic kidney disease and anemia make more red blood cells, which may reduce the need for other anemia treatments. It is for patients who are not on dialysis and do not plan to start dialysis or have a kidney transplant within the next six months.
This trial tests whether roxadustat can improve kidney oxygen levels and anemia in people with diabetic kidney disease. It may help if you have anemia from kidney problems and are being considered for medicines like erythropoietin (EPO).
This study looks at how well Daprodustat works for anemia in people with chronic kidney disease, including those on dialysis or after a kidney transplant. It collects real-world data to help doctors manage this condition.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
Hear when a new Anemia of Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.